Advertisement

Central European Journal of Medicine

, Volume 6, Issue 1, pp 123–130 | Cite as

Prognostic factors for positive immune thrombocytopenic purpura outcome after laparoscopic splenectomy

  • Mindaugas Kiudelis
  • Antanas Mickevicius
  • Ruta Dambrauskiene
  • Rolandas Gerbutavicius
  • Rasa Griniūtė
  • Dalia Adukauskiene
Research Article
  • 56 Downloads

Abstract

Laparoscopic splenectomy is considered as a second step treatment for ITP patients. The purpose of this study was to determine efficiency of laparoscopic splenectomy for ITP patients and to identify the independent prognostic factors that may predict the positive outcome. Two hundred and thirty nine patient medical records were analyzed retrospectively. The special questionnaire, which included present platelet count, the steroid usage and its dosage, was sent to all patients. The complete response (CR) was defined, when the platelet count was above 130 × 109 /L. The 239 adult patients with a median age of 51.3 (16–93 years) were included in this cohort. The median follow up period was 75 months. 49 patients, who relapsed after steroid treatment, underwent laparoscopic splenectomy. The short term postoperative CR was 71.4% after laparoscopic splenectomy compared to 38.1% in non-splenectomized patients (p < 0.000). The long term CR was 79.5 % in patients after splenectomy compared to 47.4% in non-splenectomized patients (p < 0.018). After univaried analysis three clinical variables were found to be significantly related to splenectomy outcome: disease duration (p<0.007), preoperative platelet count (p<0.049) and platelet count on the third postoperative day (p<0.000). Multiple logistic regression analysis demonstrated, that only platelet count on the 3rd postoperative day > 129 × 109 /L; RR=53.3 95% (CI, 1.888–1517.98) was significant predictor for long-term positive ITP outcome after laparoscopic splenectomy. Splenectomy is effective treatment for ITP. Platelet count > 129 × 109/L on the third postoperative day is the significant predictor of positive long-term outcome after laparoscopic splenectomy.

Keywords

Licorice Laparoscopic splenectomy ITP platelet count 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Imbach P, Kühne T, Signer E Historical aspects and present knowledge of idiopathic thrombocytopenic purpura. (2002) Br J Haematol 119:894–900CrossRefPubMedGoogle Scholar
  2. [2]
    McMillan R Therapy for adults with refractory chronic immune thrombocytopenic purpura. (1997) Ann Int Med 126(4):307–314PubMedGoogle Scholar
  3. [3]
    Stevens W, Koene H, Zwaginga JJ, Vreugdenhil G. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. (2006) Neth J Med. Nov 64(10):356–363Google Scholar
  4. [4]
    Delaitre B, Maignien B. Splenectomy by the laparoscopic approach. (1991) Report of a case. Presse Med 20:2263Google Scholar
  5. [5]
    Delaitre B, Maignien B. Laparoscopic splenectomy — Technical aspects. (1992) Surg Endosc 6:305–308CrossRefPubMedGoogle Scholar
  6. [6]
    Consensus statement Laparoscopic splenectomy: the clinical practice guidelines of the European Association for Endoscopic Surgery (EAES). (2008) Surg Endosc 22:821–848Google Scholar
  7. [7]
    Aksnes J, Abdelnoor M, Mathisen O Risk factors associated with mortality and morbidity after elective splenectomy. (1995) Eur J Surg 161: 253–258PubMedGoogle Scholar
  8. [8]
    Stasi R, Stipa E, Masi M, et al Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. (1995) American Journal of Medicine 98:436–4442CrossRefPubMedGoogle Scholar
  9. [9]
    McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. (1997) Ann Intern Med 136:307–314Google Scholar
  10. [10]
    George JN, El-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. (1994) N Engl J Med 331:1207–1211CrossRefPubMedGoogle Scholar
  11. [11]
    Stasi R, Stipa E, Masi M, et al Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. (1995) American Journal of Medicine 98:436–442CrossRefPubMedGoogle Scholar
  12. [12]
    Bourgeois E, Caulier MT, Delarozee C, et al Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis. (2003) British Journal of Haematology 120:1079–1088CrossRefPubMedGoogle Scholar
  13. [13]
    Leung AYH, Chim CS, Kwong YL, et al Clinicopathologic and prognostic features of chronic idiopathic thrombocytopenic purpura in adult Chinese patients: an analysis of 220 cases. (2001) Annals of Hematology 80:384–386CrossRefPubMedGoogle Scholar
  14. [14]
    Rodeghiero F. Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine. (2003) Haematologica 88:1081–1087PubMedGoogle Scholar
  15. [15]
    Cheng Y, Wong RS, Soo YO, et al Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. (2003) N Engl J Med 349:831–836CrossRefPubMedGoogle Scholar
  16. [16]
    Alpdogan O, Budak-AldoGan T, Ratip S, et al Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura. (1998) Br J Haemat 103:1961–1963CrossRefGoogle Scholar
  17. [17]
    Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. (2004) Mayo Clin Proc 79:504–522CrossRefPubMedGoogle Scholar
  18. [18]
    Colovic M, Dimitrijevic M, Sonnenberg C, et al Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. (2003) Hematol J 4:358–362CrossRefPubMedGoogle Scholar
  19. [19]
    George JN, Woolf SH, Raskob GE, et al Idiopathic thrombocytopenic purpura: a guideline developed by explicit methods for the American Society of Hematology. (1996) Blood 88:3–40.PubMedGoogle Scholar
  20. [20]
    Giagounidis AA, Anhuf J, Schneider P, et al Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. (2002) Eur J Haematol 69:95–100.CrossRefPubMedGoogle Scholar
  21. [21]
    Zaja F, Vianelli N, Sperotto A, et al The B-cell compartment as the selective target for the treatment of immune thrombopenias. (2003) Haematology 88:538–546Google Scholar
  22. [22]
    Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune (2003) 78:1340–1346Google Scholar
  23. [23]
    Cooper N, Stasi R, Cunningham-Rundles S, et al The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. (2004) Br J Haematol 125:232–239CrossRefPubMedGoogle Scholar
  24. [24]
    Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. (2001) Blood 98:952–957CrossRefPubMedGoogle Scholar
  25. [25]
    Braendstrup P, Bjerrum OW, Nielsen OJ, et al Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. (2005) Am J Hematol 78:275–280CrossRefPubMedGoogle Scholar
  26. [26]
    Medeot M, Zaja F, Vianelli N, et al Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: longterm follow-up results. (2008) Eur J Haematol 81(3):165–169CrossRefPubMedGoogle Scholar
  27. [27]
    Patel V, Mihatov N, Cooper N, et al Long term follow-up of patients with immune thrombocytopenic purpura whose initial response to rituximab lasted a minimum of 1 year. (2006) Blood (suppl):abstract 479Google Scholar
  28. [28]
    Kuter DJ, Bussel JB, Senecal FM, et al Evaluation of AMG 531 in nonsplenectomized patients with chronic immune thrombocytopenic purpura in a randomized placebo-controlled phase 3 study. (2007)Google Scholar
  29. [29]
    Bussel JB, Kuter DJ, de Wolf JThM, et al Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update. (2007) Blood 110:174a, abstract number 568Google Scholar
  30. [30]
    Blanchette V, Freedman J, Garvey B. Management of chronic immune thrombocytopenic purpura in children and adults. (1998) Semin Hematol 35(suppl. 1):36–51PubMedGoogle Scholar
  31. [31]
    George JN, Kojouri K, Perdue JJ, Vesely SK Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. (2000) Semin Hematol 37(3):290–298CrossRefPubMedGoogle Scholar
  32. [32]
    Maloisel F, Andres E, Zimmer J, et al Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. (2004) Am J Med 116(9):590–594CrossRefPubMedGoogle Scholar
  33. [33]
    Andrès E, Zimmer J, Noel E, et al Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol. (2003) Drugs Aging 20:841–846CrossRefPubMedGoogle Scholar
  34. [34]
    Ahn YS, Rocha R, Mylvaganam R, et al Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. (1989) Ann Int Med 111:723–729PubMedGoogle Scholar
  35. [35]
    Kim SW, Rice L, McCarthy JJ. Efficacy of danazol with autoimmune thrombocytopenia. (1997) Clin Appl Thrombosis/Hemostasis 3:251–255CrossRefGoogle Scholar
  36. [36]
    Rice L. Danazol, idiopathic thrombocytopenic purpura, and thrombopoietin. (2004) Am J Med 117(12):972–973CrossRefGoogle Scholar
  37. [37]
    Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. (2000) Arch Intern Med 160:1630–1638CrossRefPubMedGoogle Scholar
  38. [38]
    Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy forrefractory autoimmune thrombocytopenic purpura. (1995) Blood 85:351–358PubMedGoogle Scholar
  39. [39]
    Kappers-Klunne MC, van het Veer B. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. (2001) Br J Haematol 114:212–215CrossRefGoogle Scholar
  40. [40]
    Perrota S, Amendola G, Locatelli F, et al Treatment with short-term, high-dose cyclosporine A in children with refractory chronic idiopathic thrombocytopenic purpura. (2003) Br J Haematol 121:143–147CrossRefGoogle Scholar
  41. [41]
    British Committee for Standards in Haemotology Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. (2003) Br J Haematol 120:574–596Google Scholar
  42. [42]
    George JN, Woolf SH, Raskob GE, et al Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of hematology. (1996) Blood 88:3–40PubMedGoogle Scholar
  43. [43]
    Kiarash Kjouri, Sara K. Vesely, Deirdra R. Terrell et al Splenectomy for adults with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. (2004) Blood 104:2623–2632CrossRefGoogle Scholar
  44. [44]
    Stanton CJ. Laparoscopic splenectomy for idiopathic thrombocytopenic purpura (ITP): a five-year experience. (1999) Surg Endosc 13: 1083–1086CrossRefPubMedGoogle Scholar
  45. [45]
    Fabris F, Tassan T, Ramon R. et al Age as the major predictive factor of long-term response to splenectomy in immune thrombocytopenic purpura. (2001) Br J Haematol 112: 637–640CrossRefPubMedGoogle Scholar
  46. [46]
    Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. (2002) Ann Hematol 81(6):312–319CrossRefPubMedGoogle Scholar
  47. [47]
    Duperier T, Brody F, Felsher J, Walsh M, Rosen M, Ponsky J. Predictive factors for successful laparoscopic splenectomy in patients with immune thrombocytopenic purpura. (2004) Arch Surg 139: 61–66CrossRefPubMedGoogle Scholar
  48. [48]
    Katkhouda N, Grant SW, Mavor E, et al Predictors of response after laparoscopic splenectomy for immune thrombocytopenic purpura. (2001) Surg Endosc 15:484–488CrossRefPubMedGoogle Scholar
  49. [49]
    Schiavotto C, Rodeghiero F. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases. (1993) Haematologica 78: 22–28PubMedGoogle Scholar
  50. [50]
    Radaelli F, Faccini P, Goldaniga M, et al Factors predicting response to splenectomy in adult patients with idiopathic thrombocytopenic purpura. (2000) Haematologica 85:1040–1044PubMedGoogle Scholar
  51. [51]
    Ruivard M, Caulier MT, Vantelon JM. The response to high-dose intravenous immunoglobulin or steroids is not predictive of outcome after splenectomy in adults with autoimmune thrombocytopenic purpura. (1999) Br J Haematol 105:1130–1132CrossRefPubMedGoogle Scholar
  52. [52]
    Wilde RC, Ellis LD, Cooper WM. Splenectomy for chronic idiopathic thrombocytopenic purpura. (1967) Arch Surg 95:344–350PubMedGoogle Scholar
  53. [53]
    den Ottolander GJ, Gratama JW, deKoning J et al Long-term follow-up study of 168 patients with immune thrombocytopenia. (1984) Scand J Haematol 32:101–110CrossRefGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Mindaugas Kiudelis
    • 1
  • Antanas Mickevicius
    • 1
  • Ruta Dambrauskiene
    • 2
  • Rolandas Gerbutavicius
    • 2
  • Rasa Griniūtė
    • 2
  • Dalia Adukauskiene
    • 3
  1. 1.Clinic of Surgery of Kaunas University of MedicineKaunasLithuania
  2. 2.Clinic of Hematology of Kaunas University of MedicineKaunasLithuania
  3. 3.Clinic of Intensive Care of Kaunas University of MedicineKaunasLithuania

Personalised recommendations